We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+23.52%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$625M
AUM Growth
+$113M
Cap. Flow
+$47.8M
Cap. Flow %
7.65%
Top 10 Hldgs %
69.45%
Holding
35
New
10
Increased
5
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
FDMT icon
4D Molecular Therapeutics
FDMT
+$55.2M
2
DYN icon
Dyne Therapeutics
DYN
+$25.6M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$19.7M
4
PHVS icon
Pharvaris
PHVS
+$12.8M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.2M

Top Sells

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$27M
2
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$23.5M
3
JBIO
Jade Biosciences
JBIO
+$16.8M
4
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$15.9M
5
ANNX icon
Annexon
ANNX
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRDN icon
1
Viridian Therapeutics
VRDN
$2.09B
$73.3M 11.73%
3,082,622
+382,757
+14% +$9.82M
COGT icon
2
Cogent Biosciences
COGT
$6.65B
$55.5M 8.87%
4,684,132
-200,845
-4% -$2.3M
FDMT icon
3
4D Molecular Therapeutics
FDMT
$532M
$54.2M 8.67%
+3,000,000
New +$55.2M
ELVN icon
4
Enliven Therapeutics
ELVN
$3.92B
$45.5M 7.28%
2,230,127
+15,985
+0.7% +$323K
MRUS
5
DELISTED
Merus
MRUS
$45.5M 7.27%
1,726,214
+500,000
+41% +$10.9M
GHRS icon
6
GH Research
GHRS
$1.93B
$41.7M 6.67%
3,517,125
– –
AMAM
7
DELISTED
Ambrx Biopharma Inc
AMAM
$40.9M 6.54%
2,484,960
-813,617
-25% -$10.2M
KALV
8
DELISTED
KalVista Pharmaceuticals
KALV
$26.3M 4.2%
2,916,667
– –
TERN
9
DELISTED
Terns Pharmaceuticals
TERN
$26M 4.16%
2,972,869
-646,653
-18% -$7.54M
CABA icon
10
Cabaletta Bio
CABA
$437M
$25.5M 4.07%
1,973,251
– –
DYN icon
11
Dyne Therapeutics
DYN
$4.7B
$24.5M 3.91%
+2,173,913
New +$25.6M
CELC icon
12
Celcuity
CELC
$4.21B
$23.1M 3.7%
2,105,386
– –
SVRA icon
13
Savara
SVRA
$1.12B
$20.3M 3.25%
6,351,531
– –
PHVS icon
14
Pharvaris
PHVS
$2.28B
$20.1M 3.21%
+1,326,200
New +$12.8M
RYTM icon
15
Rhythm Pharmaceuticals
RYTM
$6.81B
$18M 2.87%
+1,090,000
New +$19.7M
ORIC icon
16
Oric Pharmaceuticals
ORIC
$1.15B
$16.6M 2.66%
+2,142,856
New +$12.2M
ACRS icon
17
Aclaris Therapeutics
ACRS
$726M
$10.8M 1.73%
1,040,754
– –
TRVI icon
18
Trevi Therapeutics
TRVI
$2.59B
$8.18M 1.31%
3,422,397
+372,375
+12% +$938K
APLT
19
DELISTED
Applied Therapeutics
APLT
$7.24M 1.16%
+5,658,034
New +$7.51M
THRX
20
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$7.18M 1.15%
770,000
– –
MIST icon
21
Milestone Pharmaceuticals
MIST
$138M
$6.3M 1.01%
2,208,812
– –
ADVM
22
DELISTED
Adverum Biotechnologies
ADVM
$6.18M 0.99%
+388,625
New +$4.09M
PRAX icon
23
Praxis Precision Medicines
PRAX
$8.58B
$6.1M 0.98%
+353,627
New +$5.41M
PLRX icon
24
Pliant Therapeutics
PLRX
$64.4M
$5.24M 0.84%
288,949
-1,141,051
-80% -$27M
LYRA
25
DELISTED
LYRA THERAPEUTICS INC
LYRA
$3.8M 0.61%
18,483
– –
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q2 2023 Portfolio in Review

As of Q2 2023, VR Adviser held 35 positions worth $625M, up 22% from $512M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

VR Adviser deployed $47.8M of net new capital in Q2 2023, opening 10 new positions and adding to 5 existing holdings. Its largest new stake was 4D Molecular Therapeutics: 3,000,000 shares worth $54.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Pliant Therapeutics, an estimated $27M trimmed.

  • VR Adviser's largest Q2 2023 buy was 4D Molecular Therapeutics: 3,000,000 shares worth $54.2M.
  • VR Adviser added most to Merus in Q2 2023, an estimated $10.9M increase.
  • VR Adviser's biggest Q2 2023 reduction was Pliant Therapeutics, cutting an estimated $27M.
  • VR Adviser fully exited DICE Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $23.5M.
  • VR Adviser's ten largest holdings make up 69% of its $625M portfolio in Q2 2023.
  • VR Adviser opened 10 new positions and closed 5 in Q2 2023.
  • VR Adviser's portfolio value rose 22% quarter-over-quarter to $625M.

Based on VR Adviser's 13F filing for Q2 2023, filed 11 Aug 2023.